Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap.
Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences: Q3 Sell-Off May Be Unjustified, But Long-Term Outlook A Concern
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Exact Sciences price target lowered to $75 from $85 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...
Exact Sciences Poised for Recovery and Long-Term Growth Amidst Challenges
Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...
Exact Sciences Third Quarter 2024 Earnings: Misses Expectations
Third Quarter 2024 Results Key Financial Results Revenue: US$708.7m (up 13% from ...
Yahoo Finance6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...
Investor's Business Daily on MSN6d
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...
Investopedia6d
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount
Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.
The Journal Times5d
Exact Sciences: Q3 Earnings Snapshot
MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...